Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-12-23
2011-11-29
Rawlings, Stephen (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S325000, C435S335000, C435S358000, C435S320100, C530S387100, C530S387300, C530S388230, C530S350000, C536S023500
Reexamination Certificate
active
08067199
ABSTRACT:
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 5652123 (1997-07-01), Caput et al.
patent: 5677165 (1997-10-01), De Boer et al.
patent: 5705154 (1998-01-01), Dalie et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5717072 (1998-02-01), Mosley et al.
patent: 5747037 (1998-05-01), Noelle et al.
patent: 5783181 (1998-07-01), Browne et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 5994514 (1999-11-01), Jardieu et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6143871 (2000-11-01), Bonnefoy et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: 6299875 (2001-10-01), Caplan et al.
patent: 6329509 (2001-12-01), Jardieu et al.
patent: 6468528 (2002-10-01), Mak et al.
patent: 6576232 (2003-06-01), Debinski et al.
patent: 6664227 (2003-12-01), Wynn et al.
patent: 6743604 (2004-06-01), Bonnefoy et al.
patent: 6911530 (2005-06-01), Willson et al.
patent: 7078494 (2006-07-01), Collins et al.
patent: 7078496 (2006-07-01), Collins et al.
patent: 7312024 (2007-12-01), Mak et al.
patent: 7553487 (2009-06-01), Collins et al.
patent: 7615213 (2009-11-01), Kasaian et al.
patent: 7674459 (2010-03-01), Fung et al.
patent: 2003/0049257 (2003-03-01), Mak et al.
patent: 2003/0235555 (2003-12-01), Shealey et al.
patent: 2005/0277126 (2005-12-01), Collins et al.
patent: 2008/0008648 (2008-01-01), Fung et al.
patent: 2010/0266494 (2010-10-01), Fung et al.
patent: 2011/0123530 (2011-05-01), Arron et al.
patent: 1 270 595 (2003-01-01), None
patent: 0876482 (B1) (2003-03-01), None
patent: 1 327 681 (2003-07-01), None
patent: 1 646 656 (2005-01-01), None
patent: 1141286 (B1) (2006-10-01), None
patent: 2007-161724 (2007-06-01), None
patent: 2008-500024 (2008-01-01), None
patent: WO 89/04838 (1989-06-01), None
patent: WO 91/09059 (1991-06-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 94/14975 (1994-07-01), None
patent: WO 95/14780 (1995-06-01), None
patent: WO 97/15663 (1997-05-01), None
patent: WO 97/20926 (A1) (1997-06-01), None
patent: WO 97/29131 (1997-08-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/30240 (1998-07-01), None
patent: WO 00/15663 (2000-03-01), None
patent: WO 00/23410 (2000-04-01), None
patent: WO 00/36103 (2000-06-01), None
patent: WO 00/44407 (2000-08-01), None
patent: WO 01/34645 (2001-05-01), None
patent: WO 01/92514 (2001-06-01), None
patent: WO 02/055100 (2002-07-01), None
patent: WO 03/018635 (2003-03-01), None
patent: WO 03/035847 (2003-05-01), None
patent: WO 03/040164 (2003-05-01), None
patent: WO 03/086451 (2003-10-01), None
patent: WO 2004/001655 (2003-12-01), None
patent: WO 2004/019974 (2004-03-01), None
patent: WO 2004/019975 (2004-03-01), None
patent: WO 2004/019979 (2004-03-01), None
patent: WO 2005/007699 (2005-01-01), None
patent: WO 2005/062967 (2005-07-01), None
patent: WO 2005/062972 (2005-07-01), None
patent: WO 2005/121177 (2005-12-01), None
patent: WO 2005/123126 (2005-12-01), None
patent: WO 2007/036745 (A2) (2007-04-01), None
patent: WO 2007/036745 (A3) (2007-04-01), None
patent: WO 2007/045477 (A2) (2007-04-01), None
patent: WO 2007/045477 (A3) (2007-04-01), None
patent: WO 2008/140455 (2008-11-01), None
patent: WO 2009/124090 (2009-10-01), None
Rasmussen et al. (Biotechnol. Lett. Jun. 2007; 29 (6): 845-852).
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Gussow et al. (Methods in Enzymology. 1991; 203: 99-121).
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
De Pascalis et al. (J. Immunol. 2002; 169 (6): 3076-3084).
Wu et al. (J. Mol. Biol. Nov. 19, 1999; 294 (1): 151-162).
Casset et al. (Biochem. Biophys. Res. Commun. Jul. 18, 2003; 307 (1): 198-205).
MacCallum et al. (J. Mol. Biol. Oct. 11, 1996; 262 (5): 732-745).
Holm et al. (Mol. Immunol. Feb. 2007; 44 (6): 1075-1084).
Rudikoff et al. (Proc. Natl. Acad. Sci. USA. 1982; 79 (6): 1979-1983).
Winkler et al. (J. Immunol. Oct. 15, 2000; 165 (8): 4505-4514).
Iba et al. (Protein Eng. May 1998; 11 (5): 361-70).
Kettleborough et al. (Protein Eng. Oct. 1991; 4 (7): 773-83).
U.S. Appl. No. 12/240,604, filed Dec. 29, 2008, Fung et al.
Andrews et al., 2002, “Kinetic analysis of the interleukin-13 receptor complex,” J. Biol. Chem., vol. 277(48):46073-46078.
Bellanti, 1998, “Cytokines and allergic diseases: Clinical aspects,” Allergy and Asthma, Proc., vol. 19(6):337-340.
Blanchard et al., 2005, “Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354),” Clin. Exp. Allergy, vol. 35:1096-1103.
Bost et al., 1996, “In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice,” Immunology, vol. 87(4):633-641.
Bree et al., 2007, “IL-13 blockade reduces lung inflammation afterAscaris suumchallenge in cynomolgus monkeys,” J. Allergy Clin. Immunol., vol. 119(5)1251-1257.
Brinkmann et al., 1995, “TCR-stimulated naive human CD4+45R0−T cells develop into effector cells that secrete IL-13, IL-5, and IFN-γ, but no IL-4, and help efficient IgE production by B cells,” J. Immunol., vol. 154(7):3078-3087.
Campbell et al., 2003, “Allergic humans are hypo-responsive to CXCR3 chemokines in a Thl immunity-promoting loop,” FASEB J., vol. 18(2):329-331.
Caput et al., 1996, “Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain,” J. Biol. Chem., vol. 271(28):16921-16926.
Carballido et al., 1995, “IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice,” J. Immunol., vol. 155(9):4162-4170.
Casolaro et al., 1996, “Biology and genetics of atopic disease,” Curr. Opin. Immunol., vol. 8:796-803.
De Vries et al., 1996, “Modulation of the human IgE response,” Eur. Respir. J., Suppl. 22:58s-62s.
De Vries, 1994, “Novel fundamental approaches to intervening in IgE-mediated allergic diseases,” J. Invest. Dematol., vol. 102:141-144.
Debinski et al., 1995, “A novel chimeric protein composed on interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4,” J. of Biological Chemistry, vol. 270(28):16775-16780.
Debinski et al., 1995, “Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitivity to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin,” Clinical Cancer Research, vol. 1:1253-258.
Donaldson et al., 1998, “The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1,” J. Immunol., vol. 161:2317-2324.
Doucet et al., 1998, “Interleukin (IL) 4 and IL-13 act on human lung fibroblasts,” J. Clin. Invest., vol. 101:2129-2139.
Economides, et al., 1995, “Designer cytokines: Targeting actions to cells of choice,” Science, vol. 270:1351-1353.
Enomoto et al.,
Fung Sek Chung
Huang Dan
Lu Mason
Moyle Matthew
Singh Sanjaya
Day Jones
Genentech Inc.
Rawlings Stephen
LandOfFree
Anti-IL13 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL13 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL13 antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289671